Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LCAR-M61S and LCAR-M61D in Relapsed/Refractory Multiple Myeloma
NCT06472479Phase 1Not yet recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Jul 2024
- Primary completion
- Aug 2028
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of LCAR-M61S cells in multiple myeloma (MM) (2 arms), sponsored by Jiangsu Provincial People's Hospital. Primary endpoints: Dose-limiting toxicity rate at 30 days, Treatment-emergent adverse events at 2 years and 5 more. Planned start Jul 2024; status: not yet recruiting.
02
Drugs
LCAR-M61S cells
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT06472479.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06472479.